
	Where results make sense

Topic: Ingelheim

Related Topics

Mainz

Frederick Barbarossa

Manuel I Comnenus

Charlemagne

Roma and Sinti

List of German districts

Frankfurt International Airport

	Ingelheim im Internet Infos englisch (Site not responding. Last check: 2007-10-17)
		Situated on the Rhine between Mainz (capital of Rhenish Palatinate) and the district town of Bingen at the foot of the smooth slopes of northern Rhenish Hessia, Ingelheim is protected by the hills of the ‘‘Taunus‘‘ woodlands and lies in the lowlands around the rivulet Selz.
		Sebastian Münster — theologian, geographer and historian — was born in Ingelheim in a house near the church St. Remigius in 1488.
		Ingelheim is twinned with the towns of Autun/France, Stevenage/England, San Pietro in Cariano Provence Verona/Italia, Neisse/Poland, Limbach-Oberfrohan/Sachsen and the Borough of Berlin Friedrichshain-Kreuzberg.
	www.ingelheim.de /ingelheim/E_text.htm (3579 words)

	Ingelheim
		Ingelheim am Rhein is the administrative centre of the Mainz-Bingen local government district, situated on the left bank of the Rhine.
		Several diets of The_Holy_Roman_Empire, as it was known later, were held in Ingelheim by Charlemagne and his successors.
		During the Nazi period, the same applied to Ingelheim as to all other German towns: its small but long-established Jewish minority and local Roma_and_Sinti were expelled or murdered, proven political leaders incarcerated and a great number of its young men killed in the war.
	www.ebroadcast.com.au /lookup/encyclopedia/in/Ingelheim.html (377 words)

	Ingelheim am Rhein - Wikipedia, the free encyclopedia
		Ingelheim am Rhein is the administrative centre of the Mainz-Bingen local government district, situated on the left bank of the Rhine within the federal state of Rhineland-Palatinate, Germany.
		During the Napoleonic period, the region was under French rule and Ingelheim became an administrative subcenter of the "Departement Mont-Tonnere".
		During the Nazi period, Ingelheim's development was similar to most other German towns: its small but long-established Jewish minority and local Roma and Sinti were expelled or murdered, proven political leaders incarcerated and a great number of its young men killed in the war.
	en.wikipedia.org /wiki/Ingelheim (472 words)

	Boehringer Ingelheim (Canada) Ltd./Ltée - Vetmedica (Animal Health) Division
		The links are obvious to Vetmedica, the veterinary medical arm of Boehringer Ingelheim (Canada) Ltd./Ltée, and they are an important motivator in the development and marketing of both biologicals and specialty pharmaceuticals for beef and dairy cattle, swine, companion animals and horses.
		Boehringer Ingelheim is not alone in this assessment.
		Other members of the industry turn to our veterinarians for help in identifying new diseases and formulating new therapies or new diagnostic techniques, because they are known as leaders and innovators in their field.
	www.boehringer-ingelheim.ca /vetmedica (447 words)

	Boehringer Ingelheim Nederland
		Ingelheim, Germany, November 30, 2004 - “The only answer in the fight against the AIDS pandemic is for research-driven pharmaceutical companies, generic companies, governments of industrialised and developing countries and NGOs to join forces.
		Boehringer Ingelheim has decided to accelerate this process by cooperating with the FDA to support the tentative approval of generic combination products for the PEPFAR-Programme within the scope of the licence granted.
		Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor (NPPI) tipranavir in phase III clinical trials and recently acquired the nucleoside analogue (NRTI) MIV-310 currently in phase II development.
	www.boehringer-ingelheim.nl /index.asp?cat=2&subcat=3&subsubcat=119 (815 words)

	AEGiS-PRn: Boehringer Ingelheim GmbH International Acquires New HIV/AIDS Drug from Pharmacia & Upjohn
		In the United States, Boehringer Ingelheim Pharmaceuticals, Inc. and Roxane Laboratories, Inc., are building a strong portfolio of drugs for the treatment of HIV/AIDS and related disorders.
		The Boehringer Ingelheim group of companies, with headquarters in Ingelheim (Germany) is one of the 20 leading pharmaceutical corporations in the world.
		AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you.
	www.aegis.com /news/pr/2000/PR000125.html (886 words)

	WebWire® \| Boehringer Ingelheim and Biolipox sign agreement on a new class of drugs to treat pain and inflammation (Site not responding. Last check: 2007-10-17)
		The aim of the collaboration is to develop a new class of drugs with a novel mechanism of action for the treatment of pain and inflammation.
		The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies.
		Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees.
	www.webwire.com /ViewPressRel.asp?aId=5631 (775 words)

	GlaxoSmithKline and Boehringer Ingelheim agree to assess the development of important HIV medicines for the developing ...
		Ingelheim, Germany, London, UK and Philadelphia, US, May 16, 2004 - GlaxoSmithKline plc (GSK) and Boehringer Ingelheim announced today that both companies welcome the United States' continued involvement in the global response to HIV/AIDS.
		GSK and Boehringer Ingelheim have entered into discussions to assess the development of co-packaging of anti-retrovirals for the treatment of HIV infection in the developing world.
		Headquartered in Ingelheim, Germany, it operates globally with 156 affiliates in 44 countries and a total of about 32,000 employees.
	www.gsk.com /press_archive/press2004/press_05162004.htm (394 words)

	Boehringer Ingelheim Research & Development
		As a research-driven pharmaceutical group of companies, Boehringer Ingelheim is committed to the goal of discovering and developing Products which represent high therapeutic value for patients, the physician and health care providers.
		This is achieved by first class research and development for which the Boehringer Ingelheim group of companies spent EUR 1,360 million in 2005.
		Clinical development and registration at Boehringer Ingelheim are an essential part of bringing Research and Development results to the market.
	www.boehringer-ingelheim.com /corporate/research/r_and_d.htm (316 words)

	World's fastest growing pharma company consolidates regional presence \| Boehringer Ingelheim
		Ingelheim announced the launch of its Near and Middle East regional headquarters in Dubai.
		Boehringer Ingelheim was last year the fastest growing company among the major international pharmaceutical groups with a 23% growth ranking it as number 14.
		Boehringer Ingelheim entered the Middle East market in 1960's and continues to provide innovation and technology for the treatment of respiratory, cardiovascular, central nervous system, urological and virological disorders.
	www.ameinfo.com /84473.html (614 words)

	AEGiS-PRn: Boehringer Ingelheim launches global phase III clinical trials for new anti-HIV agent Tipranavir
		Boehringer Ingelheim today announced the launch of the Phase III RESIST clinical trial program designed to further study the efficacy and safety of tipranavir for use in combination therapy for HIV-1 infection.
		Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor tipranavir.
		In 2001, Boehringer Ingelheim's RandD spending was more than EUR 1 billion which is almost a fifth of net sales in Prescription Medicines.
	www.aegis.com /news/pr/2003/PR030207.html (1324 words)

	Pharmaceutical Technology - Boehringer Ingelheim Group´s Active Ingredients Plant - Ingelheim, Germany
		Boehringer Ingelheim officially opened the new active ingredients plant in Ingelheim in early 2003.
		The initial investment of €180 million ($168 million) in the new plant is one of the largest investments made in the company's history.
		The location of the new site also means that the existing Ingelheim site will continue to play a key role in the production of drug substances in the long term.
	www.pharmaceutical-technology.com /projects/ingelheim (838 words)

	Nippon Boehringer Ingelheim
		The Boehringer Ingelheim Group in Japan consists of three companies, which are the Japanese affiliated companies of the Boehringer Ingelheim group of companies with headquarters in Germany.
		In 1885, Boehringer Ingelheim was founded Ingelheim, a small town in Germany.
		With the vision "Value through Innovation" Boehringer Ingelheim continues to make challenges as a pharmaceutical company trying to contribute to people's health and welfare by providing more valued products and services.
	www.boehringer-ingelheim.co.jp /index-e.html (243 words)

	Nippon Boehringer Ingelheim Starts Phase III Trials on Pramipexole for the Treatment of Restless Legs Syndrome (RLS)
		Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Kawanishi, Hyogo; President: Akio Ohsawa) began Phase III trials in early October on its dopamine D2 receptor agonist pramipexole to obtain approval for use in the treatment of Restless Legs Syndrome (RLS).
		The Boehringer Ingelheim group, headquartered in Ingelheim, Germany, is one of the world’s 20 leading pharmaceutical companies.
		Boehringer Ingelheim is a research driven entity, investing almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.
	www.boehringer-ingelheim.co.jp /news/p-release_e/06_1026-e.html (639 words)

	Boehringer-Ingelheim.it
		Third parties' linked sites are not under the control of Boehringer Ingelheim Italia s.p.a and no entity of the Boehringer Ingelheim Group of companies is responsible for the contents of any linked site or any link contained in a linked site, or any changes or updates to such sites.
		Neither is any entity of the Boehringer Ingelheim Group of companies responsible for webcasting or any other form of transmission received from any linked site of any third party.
		The trade names of Boehringer Ingelheim products referenced herein, whether or not appearing in bold characters or with the trademark symbol ®, are trademarks of entities of the Boehringer Ingelheim Group of companies.
	www.boehringer-ingelheim.it /condizioni_utilizzo/termofuse.php (782 words)

	Boehringer Ingelheim Pharmaceuticals Inc. (Site not responding. Last check: 2007-10-17)
		The Boehringer Ingelheim Group of companies, headquartered in Ingelheim, Germany, is a global pharmaceutical enterprise that ranks among the top 20 in the world.
		Boehringer Ingelheim Pharmaceuticals envisioned a much higher level of interaction and collaboration between its internal research teams and external partner sites, supported by a more centralized and coordinated process that would not only facilitate the exchange of information but also would provide an environment to share knowledge and expertise.
		Therefore, the goal of the eCollaboration initiative in Boehringer Ingelheim Pharmaceuticals RandD was to deploy a web-based knowledge-sharing tool between select groups within RandD and external organizations, thus improving dissemination of knowledge between Boehringer Ingelheim Pharmaceuticals and preferred external partners.
	software.emc.com /about_us/customer/profiles/bip.htm (1412 words)

	Pharmaceutical Technology - Boehringer Ingelheim Pharmaceutical Production Plant, Shanghai, China
		In March 2002 Boehringer Ingelheim opened their new manufacturing facility in Pudong, Zhangjiang High Tech Park in Shanghai.
		The subsidiary is called Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd. This is a joint venture between Boehringer Ingelheim International GMBH and Shanghai Sine Pharmaceutical Co Ltd. Boehringer Ingelheim has provided the majority of the investment and hence holds a 95% stake in the company.
		Boehringer Ingelheim's new pharmaceutical manufacturing facility in Shanghai was opened in March 2002.
	www.pharmaceutical-technology.com /projects/boehringer (517 words)

	WebWire® \| Boehringer Ingelheim 2005 - strong growth and profits once again - Spiriva® the first blockbuster (Site not responding. Last check: 2007-10-17)
		Boehringer Ingelheim achieved an operating return (operating income in relation to net sales) of 20.2%, which Professor Marbod Muff, responsible at Boehringer Ingelheim for the Corporate Board Divisions Finance and Human Resources, described as “exceptionally good”.
		In contrast, Boehringer Ingelheim expects generic meloxicam on the US market and therefore declining sales for Mobic®, its second blockbuster in 2005 after Spiriva®.
		Boehringer Ingelheim is a purely pharmaceutical company with the business segments Prescription Medicines (+17% to 7.2 billion euros), Consumer Health Care (+8% to almost 1.1 billion euros) and Animal Health (+8% to 360 million euros).
	www.webwire.com /ViewPressRel.asp?aId=12142 (1167 words)

	AIDS Activism, Boehringer Ingelheim, and the Broken Social Contract (via CobWeb/3.1 planetlab2.isi.jhu.edu) (Site not responding. Last check: 2007-10-17)
		Boehringer Ingelheim developed and brought to market the first non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune®), approved by FDA in 1996, and the tenth protease inhibitor tipranavir (Aptivus®), approved by FDA in summer 2006.
		It is not Boehringer Ingelheim's fault, or that of GFATM, PEPFAR, UNAIDS, UNICEF, or WHO that uptake of PMTCT is so pathetic—it is all of their responsibility, and that of governments that do not take care of their people.
		The fact that the dose combination which is FDA approved for use in treatment experienced individuals was now deemed too toxic for treatment naive ones indicates the alarming degree to which BI has failed to clearly define a dose which is both safe and effective for use in diverse HIV infected individuals.
	www.aidsinfonyc.org.cob-web.org:8888 /tag/tx/aidsActivism.html (7454 words)

	Boehringer Ingelheim Global Clinical Trials website: detail (Site not responding. Last check: 2007-10-17)
		At one central location everybody will be able to access key information on confirmatory clinical trials, including medical conditions being studied, number of patients and centres, as well as trial timelines.
		Results of completed trials will be made available on the Boehringer Ingelheim web page after the drug is first approved and marketed in any country within one year after trial completion.
		In addition once the IFPMA portal has been launched Boehringer Ingelheim’s clinical trial information for both ongoing and completed trials will also be assessable via the IFPMA portal.
	trials.boehringer-ingelheim.com /news/detail.jsp?newsid=3034 (364 words)

	NewsForge \| Boehringer Ingelheim Pharmaceuticals uses Linux NetworX cluster
		Ridgefield, Conn. laboratory of Boehringer Ingelheim Pharmaceuticals is using the cluster supercomputer to help predict the suitability of certain molecules in potential drugs.
		Before switching to a Linux NetworX cluster, scientists at Boehringer Ingelheim Pharmaceuticals were running the same applications on a variety of systems, but results were slowed because of the limited number of available CPUs.
		The Boehringer Ingelheim group of companies, with headquarters in Ingelheim (Germany) is one of the 20 leading pharmaceutical firms in the world and reported revenues of almost US $5.8 billion in 2000.
	www.newsforge.com /newsvac/02/04/03/1838204.shtml (658 words)

	Pharmalicensing.com: Boehringer Ingelheim: related news
		Therion Biologics licenses ICAM-1 from Boehringer Ingelheim (Sept 18 2002)
		Valentis and Boehringer Ingelheim to collaborate on rheumatoid arthritis therapy (Sept 21 1999)
		Embrex and Boehringer Ingelheim agree vaccine collaboration (Aug 30 1999)
	pharmalicensing.com /company/rn/906 (836 words)

	Boehringer Ingelheim
		Boehringer Ingelheim Austria GmbH was as pioneer at the front when at the end of the 70s the era of genetic engineering began and biotechnology was about to change forever.
		In continuation of more than 100 years of biotechnological experience and tradition at Boehringer Ingelheim, the Vienna site — founded in 1948 as Bender + Co GesmbH — was during the 80s scene of the first application of modern biotech methods for production of interferons in cell culture.
		A growing range of opportunities for basic and continuing education within Boehringer Ingelheim Austria and at the developing Biotech site in and around Vienna provide us with highly qualified employees; their motivation and commitment is one of our greatest strengths.
	www.boehringer-ingelheim.at /biopharmaceuticals (284 words)

	Boehringer Ingelheim UK - News
		Tipranavir is a non-peptidic protease inhibitor currently in Phase III of clinical development — the final stage of testing prior to the submission of data to worldwide regulatory authorities for review for marketing approval.
		In June 2004, Boehringer Ingelheim announced the enrollment of the first patient in the broader global tipranavir Compassionate Use Program, which will provide access to HIV-positive patients in desperate clinical need of new treatment options.
		Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor (NPPI) tipranavir in Phase III development and the nucleoside analogue (NRTI) alovudine in Phase II development.
	www.boehringer-ingelheim.co.uk /news/newsprint.asp?id=57 (1184 words)

	News: Boehringer Ingelheim Pharmaceuticals, Inc. Announces Agreement to Acquire Zantac(R) from Johnson & Johnson and ...
		Boehringer Ingelheim Consumer Healthcare is ranked the 8th largest supplier of self-medication products globally and the acquisition of Zantac will further strengthen their presence in the U.S. market.
		Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
		The Boehringer Ingelheim group is one of the world's 15 leading pharmaceutical companies.
	www.genengnews.com /news/bnitem.aspx?name=6869452 (557 words)

	Boehringer Ingelheim GmbH International Acquires New HIV/AIDS Drug from Pharmacia & Upjohn
		INGELHEIM, Germany and PEAPACK, N.J., Jan. 28 /PRNewswire/ -- Boehringer Ingelheim GmbH International and Pharmacia & Upjohn (NYSE: PNU) announced today that Boehringer Ingelheim has acquired worldwide rights for Pharmacia & Upjohn's investigational protease inhibitor, tipranavir.
		We have built a strong relationship with Boehringer Ingelheim through our joint development and marketing of MIRAPEX, and we are confident that this agreement will expedite the development of tipranavir," said Goran Ando, Executive Vice President and President of Research and Development of Pharmacia & Upjohn.
		In 1998 Boehringer Ingelheim spent DEM 1.6 billion (US$ 902 million) on R&D, equivalent to 18% of total sales.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-28-2000/0001126636&EDATE= (663 words)

	Kristina1701 Ingelheim am Rhein Travel Page - VirtualTourist.com
		Ingelheim is a small town of about 26,000 inhabitans, located at the Rhine river between Mainz and Bingen.
		Despite that fact that Ingelheim is home of Boehringer Ingelheim, which ranks among the world's leading pharmaceutical companies and is present in the America's, Africa, Asia, the Middle East, Australia and many European countries, the town has a rather rural character.
		Along the Rhine River in Ingelheim Nord, as well as in Ingelheim West there are lots of fruit trees and.......
	members.virtualtourist.com /m/1e372/c378 (339 words)

Try your search on: Qwika (all wikis)